

# Ross Baker

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3702072/ross-baker-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107  
papers

6,402  
citations

36  
h-index

79  
g-index

109  
ext. papers

7,373  
ext. citations

9.4  
avg, IF

5.1  
L-index

#	Paper	IF	Citations
107	Examining international practices in the management of pregnant women with von Willebrand disease. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 20, 82	15.4	2
106	Fc Binding by Fc $\beta$ 11a Is Essential for Cellular Activation by the Anti-Fc $\beta$ 11a mAbs 8.26 and 8.2. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 666813	8.4	
105	Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , <b>2021</b> , 22, 678-689	21.7	24
104	Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial. <i>Lancet</i> , <b>2021</b> , 397, 2361-2371	40	46
103	ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 1914-1921	15.4	23
102	Estradiol-Responsive miR-365a-3p Interacts with Tissue Factor 3'UTR to Modulate Tissue Factor-Initiated Thrombin Generation. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1483-1496	7	2
101	How I treat bleeding disorder of unknown cause. <i>Blood</i> , <b>2021</b> , 138, 1795-1804	2.2	2
100	Persistent endotheliopathy in the pathogenesis of long COVID syndrome. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2546-2553	15.4	60
99	Patient satisfaction after conversion from warfarin to direct oral anticoagulants for patients on extended duration of anticoagulation for venous thromboembolism - The SWAN Study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0234048	3.7	3
98	Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. <i>Haemophilia</i> , <b>2020</b> , 26, 354-362	3.3	7
97	Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients with Renal Impairment: Ikema Subgroup Analysis. <i>Blood</i> , <b>2020</b> , 136, 46-47	2.2	4
96	Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2020</b> , 58, 1322-1331	5.9	6
95	International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13. <i>International Journal of Laboratory Hematology</i> , <b>2020</b> , 42, 685-696	2.5	14
94	Clinical care of pregnant and postpartum women with COVID-19: Living recommendations from the National COVID-19 Clinical Evidence Taskforce. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2020</b> , 60, 840-851	1.7	18
93	Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. <i>Thrombosis Research</i> , <b>2019</b> , 180, 10-19	8.2	31
92	A Multicenter Trial of Vena Cava Filters in Severely Injured Patients. <i>New England Journal of Medicine</i> , <b>2019</b> , 381, 328-337	59.2	69
91	Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura. <i>Blood Research</i> , <b>2019</b> , 54, 218-228	1.4	6

90	New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. <i>Medical Journal of Australia</i> , <b>2019</b> , 210, 227-235	4	48
89	Circulating MicroRNA as Thrombosis Sentinels: Caveats and Considerations. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2018</b> , 44, 206-215	5.3	11
88	Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia. <i>Blood Research</i> , <b>2018</b> , 53, 130-137	1.4	3
87	Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1118-1127	59.2	143
86	Chronic Lymphocytic Leukaemia Is Associated with a Broad Platelet-Function Defect Which Is Exacerbated By Ibrutinib and Acalabrutinib. <i>Blood</i> , <b>2018</b> , 132, 3756-3756	2.2	
85	Unlocked nucleic acid modified primer-based enzymatic polymerization assay: towards allele-specific genotype detection of human platelet antigens.. <i>RSC Advances</i> , <b>2018</b> , 8, 32770-32774	3.7	1
84	Dimeric Fc $\alpha$ 1 ectodomains detect pathogenic anti-platelet factor 4-heparin antibodies in heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , <b>2018</b> , 16, 2520-2525	15.4	4
83	Low bleeding rates with increase or maintenance of physical activity in patients treated with recombinant factor VIII Fc fusion protein (rFVIII-Fc) in the A-LONG and Kids A-LONG Studies. <i>Haemophilia</i> , <b>2017</b> , 23, e39-e42	3.3	8
82	Identification of reference miRNAs in plasma useful for the study of oestrogen-responsive miRNAs associated with acquired Protein S deficiency in pregnancy. <i>BMC Research Notes</i> , <b>2017</b> , 10, 312	2.3	14
81	Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely Ill Medical Patients: An APEX Trial Substudy. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	6	30
80	Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIX-Fc) in subjects with haemophilia B. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 508-518	7	26
79	Construction of a Bivalent Thrombin Binding Aptamer and Its Antidote with Improved Properties. <i>Molecules</i> , <b>2017</b> , 22,	4.8	19
78	Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 534-44	59.2	286
77	Therapeutic Potential of miR-494 in Thrombosis and Other Diseases: A Review. <i>Australian Journal of Chemistry</i> , <b>2016</b> , 69, 1078	1.2	3
76	Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A. <i>Blood</i> , <b>2016</b> , 128, 630-7	2.2	59
75	Current state and novel approaches of antiplatelet therapy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 1327-38	9.4	47
74	Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 113-23	4.5	26
73	The platelet Fc receptor, Fc $\beta$ 1. <i>Immunological Reviews</i> , <b>2015</b> , 268, 241-52	11.3	60

72	Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 989-95	7	87
71	Micro-ribonucleic Acid 494 regulation of protein S expression. <i>Journal of Thrombosis and Haemostasis</i> , <b>2013</b> , 11, 1547-55	15.4	21
70	Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 2313-23	59.2	250
69	Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 411-23	4.5	180
68	Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. <i>Nature Genetics</i> , <b>2012</b> , 44, 1147-51	36.3	126
67	Validation of whole blood impedance aggregometry as a new diagnostic tool for HIT: results of a large Australian study. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 107, 575-83	7	34
66	Are myocardial infarction-associated single-nucleotide polymorphisms associated with ischemic stroke?. <i>Stroke</i> , <b>2012</b> , 43, 980-6	6.7	23
65	Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. <i>Stroke</i> , <b>2011</b> , 42, 498-500	6.7	66
64	Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study. <i>Haemophilia</i> , <b>2010</b> , 16, 615-24	3.3	27
63	Restored platelet function after romiplostim treatment in a patient with immune thrombocytopenic purpura. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 625-8	4.5	19
62	Incidence and risk factors for fatal pulmonary embolism after major trauma: a nested cohort study. <i>British Journal of Anaesthesia</i> , <b>2010</b> , 105, 596-602	5.4	62
61	PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. <i>Journal of Thrombosis and Haemostasis</i> , <b>2010</b> , 8, 1959-65	15.4	171
60	Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. <i>Hepatology</i> , <b>2009</b> , 49, 1069-82	11.2	115
59	Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. <i>Hepatology</i> , <b>2009</b> , 50, 1017-29	11.2	50
58	A rapid flow cytometric technique for the detection of platelet-monocyte complexes, activated platelets and platelet-derived microparticles. <i>International Journal of Laboratory Hematology</i> , <b>2009</b> , 31, 430-9	2.5	16
57	A novel ABCA1 nonsense mutation, R1270X, in Tangier disease associated with an unrecognised bleeding tendency. <i>Clinica Chimica Acta</i> , <b>2009</b> , 409, 136-9	6.2	13
56	Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCO) von Willebrand factor activity assays?. <i>Thrombosis Research</i> , <b>2009</b> , 123, 862-8	8.2	33
55	Potential supplementary utility of combined PFA-100 and functional von Willebrand factor testing for the laboratory assessment of desmopressin and factor concentrate therapy in von Willebrand disease. <i>Blood Coagulation and Fibrinolysis</i> , <b>2009</b> , 20, 475-83	1	17

54	Compromised ITAM-based platelet receptor function in a patient with immune thrombocytopenic purpura. <i>Journal of Thrombosis and Haemostasis</i> , <b>2008</b> , 6, 1175-82	15.4	51
53	Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2008</b> , 6, 472-5	6.9	12
52	Dual ITAM-mediated proteolytic pathways for irreversible inactivation of platelet receptors: de-ITAM-izing Fcγ <sub>3</sub> RIIa. <i>Blood</i> , <b>2008</b> , 111, 165-74	2.2	69
51	Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. <i>Thrombosis and Haemostasis</i> , <b>2007</b> , 97, 922-930	7	29
50	Routine prevention of venous thromboembolism after surgery: the time for action. <i>ANZ Journal of Surgery</i> , <b>2007</b> , 77, 408	1	
49	Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures. <i>Haemophilia</i> , <b>2007</b> , 13, 144-8	3.3	23
48	Upregulation of protein S by progestins. <i>Journal of Thrombosis and Haemostasis</i> , <b>2007</b> , 5, 2243-9	15.4	17
47	VITATOPS, the VITamins TO prevent stroke trial: rationale and design of a randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke (NCT00097669) (ISRCTN74743444). <i>International Journal of Stroke</i> , <b>2007</b> , 2, 144-50	6.3	33
46	Polymorphisms in the tissue factor pathway inhibitor gene are not associated with ischaemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , <b>2007</b> , 18, 703-8	1	10
45	Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. <i>Blood Coagulation and Fibrinolysis</i> , <b>2007</b> , 18, 559-64	1	21
44	Reducing errors in identification of von Willebrand disease: the experience of the royal college of pathologists of australasia quality assurance program. <i>Seminars in Thrombosis and Hemostasis</i> , <b>2006</b> , 32, 505-13	5.3	54
43	Association between phosphodiesterase 4D gene and ischaemic stroke. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2006</b> , 77, 1067-9	5.5	55
42	The tissue factor pathway in ischemic stroke. <i>Blood Coagulation and Fibrinolysis</i> , <b>2006</b> , 17, 527-32	1	13
41	Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. <i>Stroke</i> , <b>2005</b> , 36, 144-6	6.7	76
40	Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 2123-9	2.2	388
39	Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2005</b> , 19, 173-81	5.1	32
38	Laboratory diagnosis of von Willebrand disorder: use of multiple functional assays reduces diagnostic error rates. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , <b>2005</b> , 11, 91-7		9
37	Is there really a power shortage in clinical trials testing the "homocysteine hypothesis?". <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2004</b> , 24, e147	9.4	7

36	Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. <i>Stroke</i> , <b>2003</b> , 34, 2132-7	6.7	127
35	Protein Z in ischemic stroke and its etiologic subtypes. <i>Stroke</i> , <b>2003</b> , 34, 2415-9	6.7	62
34	Venous thromboembolism in travellers. <i>Blood Coagulation and Fibrinolysis</i> , <b>2003</b> , 14, 671-675	1	20
33	Management of platelet storage pool deficiency during pregnancy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , <b>2003</b> , 43, 171-2	1.7	4
32	Collagen platelet receptor polymorphisms integrin alpha2beta1 C807T and GPVI Q317L and risk of ischemic stroke. <i>Journal of Thrombosis and Haemostasis</i> , <b>2003</b> , 1, 963-70	15.4	34
31	Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. <i>New England Journal of Medicine</i> , <b>2003</b> , 349, 146-53	59.2	1912
30	C-reactive protein in ischemic stroke and its etiologic subtypes. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2003</b> , 12, 74-81	2.8	31
29	Investigation of coagulopathy in three cases of tiger snake ( <i>Notechis ater occidentalis</i> ) envenomation. <i>Pathology</i> , <b>2002</b> , 34, 157-61	1.6	16
28	Coagulopathy from tiger snake envenoming and its treatment: authors' reply. <i>Pathology</i> , <b>2002</b> , 34, 590	1.6	
27	Pre-operative hemostatic assessment and management. <i>Transfusion and Apheresis Science</i> , <b>2002</b> , 27, 45-53	2.4	4
26	Platelet glycoprotein Ibalpha Kozak polymorphism is associated with an increased risk of ischemic stroke. <i>Blood</i> , <b>2001</b> , 98, 36-40	2.2	78
25	Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. <i>Stroke</i> , <b>2001</b> , 32, 1793-9	6.7	104
24	Effects of regular ingestion of black tea on haemostasis and cell adhesion molecules in humans. <i>European Journal of Clinical Nutrition</i> , <b>2001</b> , 55, 881-6	5.2	61
23	Detection of protein S deficiency: a new functional assay compared to an antigenic technique. <i>Pathology</i> , <b>2000</b> , 32, 94-7	1.6	3
22	Assessment of current diagnostic practice and efficacy in testing for von Willebrand's disorder: results from the second Australasian multi-laboratory survey. <i>Blood Coagulation and Fibrinolysis</i> , <b>2000</b> , 11, 729-37	1	20
21	Determination of activated protein C resistance in anticoagulated and lupus positive patients. <i>Blood Coagulation and Fibrinolysis</i> , <b>2000</b> , 11, 439-45	1	2
20	Type 2B von Willebrand's disease in thirteen individuals from five unrelated Australian families: phenotype and genotype correlations. <i>American Journal of Hematology</i> , <b>2000</b> , 63, 197-9	7.1	6
19	Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke. <i>Stroke</i> , <b>2000</b> , 31, 1069-75	6.7	194



18	Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. <i>Circulation</i> , <b>2000</b> , 102, 2726-31	16.7	97
17	Broadsheet number 53: Activated protein C resistance: diagnosis and clinical management. <i>Pathology</i> , <b>1999</b> , 31, 365-71	1.6	
16	Methylene tetrahydrofolate reductase mutation and stroke in a monozygotic twin. <i>Australian and New Zealand Journal of Medicine</i> , <b>1998</b> , 28, 849-50		1
15	Low-molecular-weight heparin for the treatment of venous thrombosis in patients with adenocarcinoma. <i>American Journal of Hematology</i> , <b>1998</b> , 59, 260-1	7.1	13
14	Single or duplicate analysis for automated prothrombin time and activated partial thromboplastin time?. <i>Pathology</i> , <b>1997</b> , 29, 67-71	1.6	2
13	Neutrophil CD11B expression and neutrophil activation in pre-eclampsia. <i>Clinical Science</i> , <b>1997</b> , 92, 37-44.	5	90
12	Cross-reactivity to porcine factor VIII of factor VIII inhibitors in patients with haemophilia in Australia and New Zealand. <i>Australian and New Zealand Journal of Medicine</i> , <b>1997</b> , 27, 658-64		10
11	Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach. <i>American Journal of Hematology</i> , <b>1997</b> , 55, 115-7	7.1	8
10	Hepatitis C genotypes in Australian haemophilia patients. <i>Australian and New Zealand Journal of Medicine</i> , <b>1996</b> , 26, 789-92		5
9	Does activated protein C resistance increase the risk of systematic embolism in non rheumatic atrial fibrillation?. <i>Australian and New Zealand Journal of Medicine</i> , <b>1996</b> , 26, 243-4		2
8	Premature ischaemic heart disease and the gene for coagulation factor V. <i>Nature Medicine</i> , <b>1995</b> , 1, 185	50.5	45
7	Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. <i>British Journal of Haematology</i> , <b>1995</b> , 89, 117-23	4.5	58
6	Diagnosis of activated protein C resistance (factor V Leiden). <i>Lancet, The</i> , <b>1994</b> , 344, 1162	40	9
5	Pure red cell aplasia of pregnancy: a distinct clinical entity. <i>British Journal of Haematology</i> , <b>1993</b> , 85, 619-23	7.3	13
4	Bedside blood filtration and risk of thrombosis. <i>British Journal of Haematology</i> , <b>1990</b> , 75, 297-8	4.5	
3	Cytopenias induced by methotrexate in inflammatory arthritis. <i>Australian and New Zealand Journal of Medicine</i> , <b>1989</b> , 19, 747-8		2
2	Colchicine therapy for idiopathic thrombocytopenic purpura--an inexpensive alternative. <i>Australian and New Zealand Journal of Medicine</i> , <b>1989</b> , 19, 412-3		3
1	Platelet function in myeloproliferative disorders: characterization and sequential studies show multiple platelet abnormalities, and change with time. <i>European Journal of Haematology</i> , <b>1988</b> , 40, 267-72	2.8	50

